These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17983482)

  • 21. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
    Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
    Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of HER2/HER3 co-receptor in breast carcinogenesis.
    Way TD; Lin JK
    Future Oncol; 2005 Dec; 1(6):841-9. PubMed ID: 16556064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
    Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
    Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
    Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
    Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
    Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
    Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
    Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR
    Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
    Hsieh AC; Moasser MM
    Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
    Momeny M; Saunus JM; Marturana F; McCart Reed AE; Black D; Sala G; Iacobelli S; Holland JD; Yu D; Da Silva L; Simpson PT; Khanna KK; Chenevix-Trench G; Lakhani SR
    Oncotarget; 2015 Feb; 6(6):3932-46. PubMed ID: 25668816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review.
    Geng W; Thomas H; Chen Z; Yan Z; Zhang P; Zhang M; Huang W; Ren X; Wang Z; Ding K; Zhang J
    Eur J Pharmacol; 2024 Aug; 977():176725. PubMed ID: 38851563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
    Albanell J; Codony J; Rovira A; Mellado B; Gascón P
    Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
    Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
    J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.
    Kirkegaard T; Yde CW; Kveiborg M; Lykkesfeldt AE
    Int J Oncol; 2014 Jul; 45(1):393-400. PubMed ID: 24819550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological and clinical significance of HER2 overexpression in breast cancer.
    Kurebayashi J
    Breast Cancer; 2001; 8(1):45-51. PubMed ID: 11180765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
    Chen CH; Chernis GA; Hoang VQ; Landgraf R
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9226-31. PubMed ID: 12874383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The upgraded role of HER3 and HER4 receptors in breast cancer.
    Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
    Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.